MetaCap

Editas Medicine (EDIT) vs SAB Biotherapeutics (SABS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SAB Biotherapeutics (SABS) has outperformed Editas Medicine (EDIT) over the past year, losing 28.9% versus a loss of 32.2%. Over five years, EDIT leads with a -94.9% price change compared with -97.3% for SABS. SAB Biotherapeutics is the larger company by market cap ($253.1 million vs $253.1 million), about 1.0 times the size, while Editas Medicine is growing revenue faster (+25.4% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDIT-32.23%SABS-28.86%
+60%+9%-42%
Nov 21, 20251 yearNov 20, 2026
EDIT-95.36%SABS-97.45%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDIT versus SABS key metrics
MetricEDITSABS
Share price$1.64$2.81
Market cap$253.12M$253.15M
1-day change-4.09%-3.44%
YTD return-20.00%-24.87%
1-year return-32.23%-28.86%
5-year return-94.93%-97.32%
EPS (TTM)$-0.54$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$40.52M$0
Revenue growth (YoY)+25.39%-100.00%
Net income (latest FY)$-160.06M$13.27M
Operating margin-394.89%—
Net margin-395.01%—
52-week high$3.94$5.15
52-week low$1.63$2.44
Distance from 52-week high-58.38%-45.44%
Analyst consensusbuystrong_buy
Avg. price target upside+271.95%+314.23%
Average volume2.63M633.60K
Shares outstanding154.34M90.09M
Employees8786
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Editas Medicine grew revenue faster in its latest fiscal year (+25.39% vs -100.00%).

About Editas Medicine

EDIT stock →

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

EDIT vs SABS FAQ

Which is bigger, Editas Medicine or SAB Biotherapeutics?

SAB Biotherapeutics (SABS) is larger, with a market capitalization of $253.15M compared with $253.12M for Editas Medicine (EDIT).

Which stock has performed better over the past year, EDIT or SABS?

SABS returned -28.86% over the past 12 months, compared with -32.23% for EDIT (price return, excluding dividends). Past performance does not predict future results.

Are Editas Medicine and SAB Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons